John Blankenship

John Blankenship

Company: Novartis

Job title: Senior Investigator & Group Leader - Antibody Discovery


Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space – What Does the Future of the BioSpecific Look Like? 3:30 pm

• What leads to a program being pulled from the clinic? • What are early warning signs that have proved good predictors of failures in scale up? • At which stage are failures typically occurring and why? • Investigating the relative roles of factors such as manufacturability, toxicity and selectivityRead more

day: Day Two

Panel Discussion: Solving the Specificity Problem to Pioneer Bispecifics in Solid Tumor Indications 9:25 am

Understanding the specific requirements for therapeutics targeting solid tumor indications and contrasting them with hematological malignancies Mitigating against on-target off-tumor toxicities by establishing more nuanced targeting approaches Lessons learned from solid tumor targeting with a range of therapeutics – how can these strategies be applied to the bispecific space?Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.